Phase IIb/III efficacy and safety study
Research payments
$9,109
Through program year 2020, $9,109 in research payments was reported against Phase IIb/III efficacy and safety study, across 265 payments, paid by Boehringer Ingelheim RCV GmbH & Co KG.
- Paid by
- Boehringer Ingelheim RCV GmbH & Co KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $1,300 | 68 |
| 2019 | Research | $7,809 | 197 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Stacy Croteau Boston, MA Named on 36 payments
- Colleen Druzgal Charlottesville, VA Named on 36 payments
- John Puetz Bridgeton, MO Named on 35 payments
- Anjali Pawar Sacramento, CA Named on 30 payments
- Judy Felgenhauer Spokane, WA Named on 25 payments
- Natalia Dixon Winston Salem, NC Named on 24 payments
- Erin Cockrell Tampa, FL Named on 20 payments
- Fernando Corrales-Medina Miami, FL Named on 18 payments
- Alan Ikeda Las Vegas, NV Named on 13 payments
- Wendy Woods Swafford Des Moines, IA Named on 10 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.